- May 5, 2026 - Research presented at Digestive Disease Week 2026 strengthens the evidence base for precision obesity medicine, demonstrating its utility across both surgical and pharmacological treatments
In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight -- about 25 pounds on average -- over more than 16 months
Sugar reduction is a hot topic across various consumer groups
Case reports don't prove causality, because you don't know if that person would have developed pancreatitis otherwise, said Ronald Goldenberg, a consultant endocrinologist emeritus at LMC Diabetes & Endocrinology who was involved in some of the earliest clinical trials testing GLP-1 drugs
The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan
Obesity as a Public Health Crisis and Contemporary Therapies Between 2021 and 2023, the prevalence of obesity, defined as a body-mass index (BMI, weight in kilograms divided by square of height in meters) 30, in adults in the United States increased to 40.3%, with no significant differences between men and women [6]
